Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

Toshiki Terao; Junichiro Yuda; Nobuhiko Yamauchi; Yong Mei Guo; Kaoru Shimada; Masato Sugano; Genichiro Ishii; Yosuke Minami

doi:10.3892/MCO.2021.2287

Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

Toshiki Terao, Junichiro Yuda, Nobuhiko Yamauchi, Yong Mei Guo, Kaoru Shimada, Masato Sugano, Genichiro Ishii, Yosuke Minami

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.

Original language	English
Article number	125
Journal	Molecular and Clinical Oncology
Volume	14
Issue number	6
DOIs	https://doi.org/10.3892/MCO.2021.2287
Publication status	Published - 2021
Externally published	Yes

Keywords

Brentuximab vedotin
CD30
Gray zone lymphoma
Refractory
Relapsed

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/MCO.2021.2287

Cite this

@article{4444b21eea1d4938a0f3d4c42d8a7dff,

title = "Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission",

abstract = "Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.",

keywords = "Brentuximab vedotin, CD30, Gray zone lymphoma, Refractory, Relapsed",

author = "Toshiki Terao and Junichiro Yuda and Nobuhiko Yamauchi and Guo, {Yong Mei} and Kaoru Shimada and Masato Sugano and Genichiro Ishii and Yosuke Minami",

year = "2021",

doi = "10.3892/MCO.2021.2287",

language = "English",

volume = "14",

journal = "Molecular and Clinical Oncology",

issn = "2049-9450",

publisher = "Spandidos Publications UK",

number = "6",

}

TY - JOUR

T1 - Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

AU - Terao, Toshiki

AU - Yuda, Junichiro

AU - Yamauchi, Nobuhiko

AU - Guo, Yong Mei

AU - Shimada, Kaoru

AU - Sugano, Masato

AU - Ishii, Genichiro

AU - Minami, Yosuke

PY - 2021

Y1 - 2021

N2 - Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.

AB - Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.

KW - Brentuximab vedotin

KW - CD30

KW - Gray zone lymphoma

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85106688282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106688282&partnerID=8YFLogxK

U2 - 10.3892/MCO.2021.2287

DO - 10.3892/MCO.2021.2287

M3 - Article

AN - SCOPUS:85106688282

SN - 2049-9450

VL - 14

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

IS - 6

M1 - 125

ER -

Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this